Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02626663

The Role of Microparticles as a Biomarker

Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:
The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)

Clinical Trial Summary

The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02626663
Study type Observational
Source University of Rochester
Contact
Status Withdrawn
Phase
Start date July 2016
Completion date December 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Recruiting NCT05785468 - A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
Completed NCT04074187 - A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Phase 2/Phase 3
Terminated NCT00953771 - Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) Phase 2
Recruiting NCT01257269 - Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Not yet recruiting NCT05568147 - Aspirin for Prophylaxis of TTP Phase 2/Phase 3
Recruiting NCT05468320 - Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Phase 3
Completed NCT00713193 - Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Completed NCT00426686 - ADAMTS13 in Thrombotic Thrombocytopenic Purpura N/A
Withdrawn NCT00251277 - Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Phase 1/Phase 2
Recruiting NCT04588194 - Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia Phase 2
Active, not recruiting NCT03237819 - Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Phase 3
Completed NCT00907751 - Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Phase 2
Completed NCT03369314 - Observational Study of the Use of octaplasLG®.
Terminated NCT01938404 - Octaplas Adult TTP Trial
Recruiting NCT04981028 - The ConNeCT Study: Neurological Complications of TTP
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Recruiting NCT05389007 - .German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Terminated NCT00593229 - International Registry and Biorepository for TMA(Thrombotic Microangiopathy) N/A